A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. (Q45158856)
Jump to navigation
Jump to search
scientific article published on 22 November 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. |
scientific article published on 22 November 2004 |
Statements
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer (English)